SynthesisMolecular diversity2026
1,8-naphthalimide-based DNA intercalators and anticancer agents: a systematic review.
Synthesis in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Benzofuran-Annulated Naphthalimides Trigger Replication Stress, DNA Damage, and p53-Dependent Cell Cycle Arrest.Pharmaceutics · 2026Article
- Benzodioxin-Annulated Naphthalimides as Potent DNA Replication Stress Inducers with Dual p53-Dependent and Independent Antitumor Activity.Pharmaceutics · 2026Article
- Thiazole derivatives in cancer therapy: mechanistic insights, bioactivity, and future perspective.Future medicinal chemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1,8-Naphthalimide derivatives have emerged as versatile scaffolds in anticancer drug development due to their efficient DNA-intercalating ability and diverse mechanisms of action, including Topoisomerase I/II inhibition and photoinduced DNA cleavage. These structural features contribute to their potent cytotoxicity and broad-spectrum anticancer activity. This manuscript offers a focused yet comprehensive overview of recent advances in the design and biological evaluation of 1,8-naphthalimide-based intercalators. The compounds are systematically categorized into mono-intercalators, fused-ring-extended analogs, photoactive agents, bifunctional conjugates, and organometallic hybrids. For each class, we discuss structure-activity relationships, cytotoxic profiles, and mechanistic insights relevant to anticancer efficacy. Distinct from previous reviews, this work provides an integrated perspective across multiple structural classes, emphasizing their translational potential and guiding future rational design of naphthalimide-based therapeutics.
Indexed as
Identifiers
40533630What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.